Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04821375 · ClinicalTrials.gov registry record · Early Phase 1

Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

A Early Phase 1 study, sponsored by Carol Fabian, MD.

Completed
Registry status
Early Phase 1
Development phase
16
Enrollment target

NCT04821375: Completed Early Phase 1 study, sponsored by Carol Fabian, MD.

NCT04821375 is a Early Phase 1 study that has completed, run by Carol Fabian, MD. The registered enrollment target is 16 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04821375, a Early Phase 1 study, has completed, sponsored by Carol Fabian, MD.

COMPLETED
Registry status
Early Phase 1
Development phase
16 participants
Enrollment target

Study Summary

Pilot study to test feasibility of 6 months of bazedoxifene (BZA) plus conjugated estrogens (CE) to modulate breast MRI parameters.

Primary Outcome

Trial design is acceptable to potential subjects, as evidenced by participation

Interventions

  • DRUG bazedoxifene plus conjugated estrogens

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2021-12-02
Est. Completion 2024-12-31
Phase Early Phase 1
Carol Fabian, MD

14 total trials

What the finished NCT04821375 record still lists

NCT04821375 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 1 intervention - of which bazedoxifene plus conjugated estrogens is the first listed.

NCT04821375 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04821375 about?

NCT04821375 is a clinical study titled "Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers". Pilot study to test feasibility of 6 months of bazedoxifene (BZA) plus conjugated estrogens (CE) to modulate breast MRI parameters.

What is the current status of trial NCT04821375?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2021-12-02. Estimated completion is 2024-12-31.

What interventions are being tested in trial NCT04821375?

The interventions under investigation include: bazedoxifene plus conjugated estrogens (DRUG).

Who is sponsoring clinical trial NCT04821375?

This trial is sponsored by Carol Fabian, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04821375's enrollment target sits among peer trials

16 1370th of 2000 higher than 598 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04821375, the US trial registry maintained by the National Library of Medicine. NCT04821375 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.